LAB - Standard BioTools Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
South San Francisco,
United States
Type: Equity
LAB price evolution
LAB
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $19.66 | $16.56 | $15.12 | $14.5 |
| Inventory | $20.53 | $21.93 | $22.08 | $22.51 |
| Total current assets | $158.22 | $170.74 | $183.07 | $194.93 |
| Long term investments | ||||
| Property, plant & equipment | $54.85 | $55.73 | $56.72 | $57.98 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $323.07 | $339.29 | $355.83 | $371.65 |
| Current liabilities | ||||
| Accounts payable | $9.24 | $7.33 | $6.09 | $6.11 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $109.33 | $51.8 | $46.84 | $43.79 |
| Long term debt | $3.98 | $59.59 | $60.66 | $61.73 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $159.87 | $159.75 | $157.96 | $157.55 |
| Shareholders' equity | ||||
| Retained earnings | -$1000.75 | -$980.98 | -$959.98 | -$942.94 |
| Other shareholder equity | -$2.22 | -$1.95 | -$1.55 | -$1.33 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $47.82 | |||
| Short term investments | ||||
| Net receivables | $19.66 | $17.28 | $18.32 | $25.42 |
| Inventory | $20.53 | $21.47 | $20.82 | $19.69 |
| Total current assets | $158.22 | $208.81 | $72.07 | $117.66 |
| Long term investments | ||||
| Property, plant & equipment | $54.85 | $59.53 | $65.15 | $55.65 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $323.07 | $390.31 | $275.21 | $324.76 |
| Current liabilities | ||||
| Accounts payable | $9.24 | $7.91 | $10.6 | $9.22 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $109.33 | $43.44 | $49.57 | $54.25 |
| Long term debt | $3.98 | $62.81 | $64.21 | $54.22 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $159.87 | $160.52 | $180.62 | $185.71 |
| Shareholders' equity | ||||
| Retained earnings | -$1000.75 | -$926.1 | -$736 | -$676.76 |
| Other shareholder equity | -$2.22 | -$81.47 | -$0.91 | $0.11 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $26.5 | $38.27 | ||
| Cost of revenue | ||||
| Gross Profit | $12.24 | $20.24 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $39.74 | $31.5 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.57 | -$0.81 | ||
| Interest expense | -$38.82 | -$1.07 | ||
| Net income | ||||
| Net income | -$76.29 | -$9.43 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $130.58 | $138.14 | $117.24 | $112.96 |
| Cost of revenue | ||||
| Gross Profit | $69.37 | $83.33 | $64.28 | $61.65 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $136.83 | $134.36 | $116.12 | $109.82 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$4.42 | -$1.08 | -$1.92 | -$2.41 |
| Interest expense | -$3.82 | -$3.57 | -$4.28 | -$13.89 |
| Net income | ||||
| Net income | -$59.24 | -$53.02 | -$64.79 | -$59.01 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$128.37 | -$139.11 | -$0.87 | -$11.95 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $231.03 | $231.03 | $18.07 | $15.96 |
| Effect of exchange rate | -$0.72 | -$0.44 | -$0.09 | -$0.02 |
| Change in cash and equivalents | $31.75 | $45.91 | $1.52 | -$40.07 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$11.95 | $39.98 | -$39.3 | $4.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $15.96 | $20.86 | $2.79 | $57.66 |
| Effect of exchange rate | -$0.02 | $0.39 | $0.06 | $0.17 |
| Change in cash and equivalents | -$40.07 | $45.81 | -$71.66 | $37.35 |
News
Fundamentals
| Market cap | $205.39M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 80.23M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.45 |
| Quick ratio | 1.26 |